X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ABBOTT INDIA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ABBOTT INDIA STERLING BIOTECH/
ABBOTT INDIA
 
P/E (TTM) x -0.4 36.7 - View Chart
P/BV x 0.0 9.4 0.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   ABBOTT INDIA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ABBOTT INDIA
Mar-18
STERLING BIOTECH/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs116,110 0.2%   
Low Rs33,996 0.1%   
Sales per share (Unadj.) Rs26.81,552.2 1.7%  
Earnings per share (Unadj.) Rs-15.0188.8 -7.9%  
Cash flow per share (Unadj.) Rs-5.5196.4 -2.8%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs54.9796.6 6.9%  
Shares outstanding (eoy) m267.8721.25 1,260.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.3 8.0%   
Avg P/E ratio x-0.526.8 -1.7%  
P/CF ratio (eoy) x-1.325.7 -4.9%  
Price / Book Value ratio x0.16.3 2.0%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m1,862107,376 1.7%   
No. of employees `0001.43.3 40.8%   
Total wages/salary Rs m5473,937 13.9%   
Avg. sales/employee Rs Th5,303.39,929.3 53.4%   
Avg. wages/employee Rs Th403.81,185.1 34.1%   
Avg. net profit/employee Rs Th-2,959.01,207.7 -245.0%   
INCOME DATA
Net Sales Rs m7,18132,985 21.8%  
Other income Rs m431,170 3.6%   
Total revenues Rs m7,22334,155 21.1%   
Gross profit Rs m9475,245 18.1%  
Depreciation Rs m2,543162 1,570.8%   
Interest Rs m4,37738 11,458.4%   
Profit before tax Rs m-5,9316,215 -95.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,203 -87.4%   
Profit after tax Rs m-4,0074,012 -99.9%  
Gross profit margin %13.215.9 82.9%  
Effective tax rate %32.435.4 91.5%   
Net profit margin %-55.812.2 -458.7%  
BALANCE SHEET DATA
Current assets Rs m14,33522,655 63.3%   
Current liabilities Rs m49,8096,681 745.6%   
Net working cap to sales %-494.048.4 -1,020.1%  
Current ratio x0.33.4 8.5%  
Inventory Days Days40365 622.7%  
Debtors Days Days17129 585.4%  
Net fixed assets Rs m55,432835 6,634.9%   
Share capital Rs m268213 126.1%   
"Free" reserves Rs m13,93516,715 83.4%   
Net worth Rs m14,70116,928 86.8%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98824,162 306.2%  
Interest coverage x-0.4163.7 -0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.11.4 7.1%   
Return on assets %0.516.8 3.0%  
Return on equity %-27.323.7 -115.0%  
Return on capital %-6.436.9 -17.4%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860369 504.6%   
Fx outflow Rs m253,807 0.7%   
Net fx Rs m1,835-3,438 -53.4%   
CASH FLOW
From Operations Rs m1,7191,527 112.6%  
From Investments Rs m-3,148-2,148 146.5%  
From Financial Activity Rs m1,426-1,024 -139.2%  
Net Cashflow Rs m-3-1,646 0.2%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 7.9 -  
FIIs % 9.9 0.1 9,900.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.1 229.8%  
Shareholders   21,482 18,270 117.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS